Nothing Special   »   [go: up one dir, main page]

PT1390525E - Piruvato-quinase como uma nova molécula alvo - Google Patents

Piruvato-quinase como uma nova molécula alvo Download PDF

Info

Publication number
PT1390525E
PT1390525E PT02748716T PT02748716T PT1390525E PT 1390525 E PT1390525 E PT 1390525E PT 02748716 T PT02748716 T PT 02748716T PT 02748716 T PT02748716 T PT 02748716T PT 1390525 E PT1390525 E PT 1390525E
Authority
PT
Portugal
Prior art keywords
pyruvate
kinase
target molecule
novel target
target
Prior art date
Application number
PT02748716T
Other languages
English (en)
Inventor
Gyorgy Keri
Axel Ullrich
Attila Stetak
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of PT1390525E publication Critical patent/PT1390525E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02748716T 2001-05-23 2002-05-23 Piruvato-quinase como uma nova molécula alvo PT1390525E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112601 2001-05-23

Publications (1)

Publication Number Publication Date
PT1390525E true PT1390525E (pt) 2008-11-25

Family

ID=8177529

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02748716T PT1390525E (pt) 2001-05-23 2002-05-23 Piruvato-quinase como uma nova molécula alvo

Country Status (10)

Country Link
US (2) US20040152648A1 (pt)
EP (2) EP1390525B8 (pt)
AT (1) ATE404691T1 (pt)
AU (1) AU2002319180B2 (pt)
CA (1) CA2448165A1 (pt)
DE (1) DE60228233D1 (pt)
DK (1) DK1390525T3 (pt)
ES (1) ES2312595T3 (pt)
PT (1) PT1390525E (pt)
WO (1) WO2002095063A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016646A2 (en) * 2002-08-12 2004-02-26 Amynon Bio Tech Gmbh Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
WO2004058153A2 (en) * 2002-12-20 2004-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
WO2006055880A2 (en) * 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
US20060166236A1 (en) * 2004-12-15 2006-07-27 Chong-Sheng Yuan Allosteric enzyme coupled immunoassay (AECIA)
US8552050B2 (en) * 2007-08-16 2013-10-08 Beth Israel Deaconess Medical Center Activators of pyruvate kinase M2 and methods of treating disease
US8841305B2 (en) 2008-10-09 2014-09-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of the human pyruvate kinase M2 receptor
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
PL2427441T3 (pl) 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Aktywatory PKM2 do stosowania w leczeniu raka
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
JP5764555B2 (ja) 2009-06-29 2015-08-19 アジオス ファーマシューティカルズ, インコーポレイテッド 治療組成物および関連する使用方法
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011109823A1 (en) 2010-03-05 2011-09-09 The Trustees Of Columbia University In The City Of New York Inhibitory rnas to rna binding proteins hnrnpa1, hnrnpa2 and ptb and uses thereof
EP2563761A1 (en) 2010-04-29 2013-03-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
EP3307271B1 (en) 2015-06-11 2023-09-13 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
CA3024181C (en) 2017-03-20 2023-06-13 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
MA53668A (fr) 2018-09-19 2021-09-15 Forma Therapeutics Inc Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
WO1998035032A2 (en) * 1997-02-11 1998-08-13 The Regents Of The University Of California Methods of inducing cell cycle stasis
US7074895B2 (en) * 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
US5948628A (en) * 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay

Also Published As

Publication number Publication date
EP1390525A1 (en) 2004-02-25
WO2002095063A1 (en) 2002-11-28
US20080021116A1 (en) 2008-01-24
EP1990422A1 (en) 2008-11-12
CA2448165A1 (en) 2002-11-28
DE60228233D1 (de) 2008-09-25
EP1390525B1 (en) 2008-08-13
EP1390525B8 (en) 2009-03-04
ES2312595T3 (es) 2009-03-01
ATE404691T1 (de) 2008-08-15
DK1390525T3 (da) 2008-12-08
US20040152648A1 (en) 2004-08-05
AU2002319180B2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
PT1390525E (pt) Piruvato-quinase como uma nova molécula alvo
IL202688A0 (en) Novel use of a compound for treating diabetic neuropathic pain
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
IL176674A0 (en) Fc region variants
HK1087628A1 (en) Prodrugs of gaba analogs, compositions and uses thereof gaba
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
SE0202838D0 (sv) Chemical compounds
IL175770A0 (en) Novel use of peptide compounds for treating central neuropathic pain
AU9475001A (en) Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0325956D0 (en) Novel compounds
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO1999061398A3 (en) 24-hydroxyvitamin d, analogs and uses thereof
IL175762A0 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
BR0214230A (pt) Compostos e processos de fabricação de compostos
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
SE0101082D0 (sv) Novel use
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
TW200505435A (en) Treatment of ocular disorders
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
NO20033401L (no) Kjemiske forbindelser
IL164536A (en) Use of hydroxypyridone-derivatives in the preparation of pharmaceuticals for wound healing
AU2003249999A8 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours